Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H

20260 citationsJournal Articlegreen Open Access

Authors

April K.S. Salama · Duke University

V Wang · Dana-Farber Cancer Institute

Erin R. Macrae · Columbus Oncology and Hematology Associates

Jong-In Park · Medical College of Wisconsin

Helen X. Chen · National Cancer Institute

Robert J. Gray · Dana-Farber Cancer Institute

Lisa M. McShane

Abstract

This study confirms the clinical benefit of dabrafenib + trametinib in BRAFV600-mutated solid tumors, supporting the recent tumor-agnostic regulatory approval of this combination.

Topics & Keywords

Lung Cancer Treatments and Mutations Melanoma and MAPK Pathways Synthesis and Biological Activity

Publication Details

Published in: JCO Precision Oncology

Volume 10, Issue 1, pp. e2500338-e2500338

DOI: 10.1200/po-25-00338

Field-Weighted Citation Impact: 0.00

Command Palette

Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> <sup> <i>V600E</i> </sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H

Authors

Abstract

Topics & Keywords

Publication Details